U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H25N3O2S
Molecular Weight 335.466
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALMOTRIPTAN

SMILES

CN(C)CCc1c[nH]c2ccc(cc12)CS(=O)(=O)N3CCCC3

InChI

InChIKey=WKEMJKQOLOHJLZ-UHFFFAOYSA-N
InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3

HIDE SMILES / InChI
TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AXERT

Approved Use

Almotriptan tablets, USP are a 5HT1B/1D receptor agonist (triptan) indicated for: •Acute treatment of migraine attacks in adults with a history of migraine with or without aura (1.1) •Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more (1.1) Important Limitations: •Use only after a clear diagnosis of migraine has been established (1.2) •In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms was not established (1.2) •Not intended for the prophylactic therapy of migraine (1.2) •Not indicated for the treatment of cluster headache (1.2) 1.1 Acute Treatment of Migraine Attacks Adults Almotriptan tablets, USP are indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura. Adolescents Age 12 to 17 Years Almotriptan tablets are indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). 1.2 Important Limitations Almotriptan tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with almotriptan tablets, the diagnosis of migraine should be reconsidered before almotriptan tablets are administered to treat any subsequent attacks. In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. Almotriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine [see Contraindications (4.7)

Launch Date

989193600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
52.6 ng/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALMOTRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
312 ng × h/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALMOTRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.1 h
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ALMOTRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.5 h
unknown, oral
ALMOTRIPTAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
unknown, oral
ALMOTRIPTAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 mg single, intravenous
Dose: 3 mg
Route: intravenous
Route: single
Dose: 3 mg
Sources:
healthy, 19-33 years
Health Status: healthy
Age Group: 19-33 years
Sex: M
Sources:
10 mg single, subcutaneous
Highest studied dose
Dose: 10 mg
Route: subcutaneous
Route: single
Dose: 10 mg
Sources:
unhealthy, 42 years (range: 18-72 years)
Health Status: unhealthy
Age Group: 42 years (range: 18-72 years)
Sex: M+F
Sources:
12.5 mg multiple, oral
Recommended
Dose: 12.5 mg
Route: oral
Route: multiple
Dose: 12.5 mg
Sources:
unhealthy, 42 years (range: 18-72 years)
Health Status: unhealthy
Age Group: 42 years (range: 18-72 years)
Sex: M+F
Sources:
Disc. AE: Chest pain, Electrocardiogram QTc interval prolonged...
AEs leading to
discontinuation/dose reduction:
Chest pain (0.9%)
Electrocardiogram QTc interval prolonged (0.7%)
Sources:
100 mg multiple, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, adult
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
healthy, adult
AEs

AEs

AESignificanceDosePopulation
Electrocardiogram QTc interval prolonged 0.7%
Disc. AE
12.5 mg multiple, oral
Recommended
Dose: 12.5 mg
Route: oral
Route: multiple
Dose: 12.5 mg
Sources:
unhealthy, 42 years (range: 18-72 years)
Health Status: unhealthy
Age Group: 42 years (range: 18-72 years)
Sex: M+F
Sources:
Chest pain 0.9%
Disc. AE
12.5 mg multiple, oral
Recommended
Dose: 12.5 mg
Route: oral
Route: multiple
Dose: 12.5 mg
Sources:
unhealthy, 42 years (range: 18-72 years)
Health Status: unhealthy
Age Group: 42 years (range: 18-72 years)
Sex: M+F
Sources:
Overview

Overview

Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Comparative aspects of triptans in treating migraine.
2001
Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers.
2001 Feb
Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.
2001 Feb
[Migraine headache. Severe attacks: triptans are essential].
2001 Jul 19
Acute treatment of migraine and the role of triptans.
2001 Mar
Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers.
2001 Mar
Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study.
2001 Nov
Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine.
2001 Nov 27
Gateways to clinical trials.
2002 Dec
A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine.
2002 Jan
Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better.
2002 Jan
[Treatment of migraine in patients with hypertension and ischemic heart disease].
2002 Jan 20
A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine.
2003 Feb
[Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study].
2003 Jan-Feb
Almotriptan versus rizatriptan in patients with migraine in Spain.
2003 Jul-Aug
Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.
2003 Nov
Gateways to clinical trials.
2004 Jan-Feb
Evaluating triptan usage: a rebuttal.
2004 Oct
Pharmacokinetics and safety of oral almotriptan in healthy male volunteers.
2004 Oct
Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).
2004 Sep
Correlation between lipophilicity and triptan outcomes.
2005 Jan
Patents

Patents

Sample Use Guides

Adults and adolescents age 12 to 17 years: 6.25 mg or 12.5 mg single
Route of Administration: Oral
In vitro Almotriptan showed selectivity of action for migraine-related human arteries (i.e. contractile EC(50) of 30 and 700 nm for meningeal and temporal arteries, respectively), whereas the effect on arteries supplying blood to the brain was lower.
Name Type Language
ALMOTRIPTAN
INN   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE
Systematic Name English
ALMOTRIPTAN [USAN]
Common Name English
ALMOTRIPTAN [INN]
Common Name English
LAS-31416
Code English
LAS 31416
Code English
ALMOTRIPTAN [VANDF]
Common Name English
ALMOTRIPTAN [WHO-DD]
Common Name English
ALMOTRIPTAN [MI]
Common Name English
PYRROLIDINE, 1-(((3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-5-YL)METHYL)SULFONYL)-
Systematic Name English
NSC-760092
Code English
Classification Tree Code System Code
WHO-VATC QN02CC05
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
NDF-RT N0000175764
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
NCI_THESAURUS C47794
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
LIVERTOX 27
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
NDF-RT N0000175763
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
NDF-RT N0000175765
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
WHO-ATC N02CC05
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
Code System Code Type Description
CAS
154323-57-6
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
DRUG CENTRAL
128
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL1505
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
MERCK INDEX
M1568
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00918
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
IUPHAR
7110
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
RXCUI
279645
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY RxNorm
MESH
C409045
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
EPA CompTox
154323-57-6
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
WIKIPEDIA
ALMOTRIPTAN
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
FDA UNII
1O4XL5SN61
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
NCI_THESAURUS
C65224
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
EVMPD
SUB05350MIG
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
INN
7463
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
LACTMED
Almotriptan
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY
PUBCHEM
123606
Created by admin on Fri Jun 25 22:11:59 UTC 2021 , Edited by admin on Fri Jun 25 22:11:59 UTC 2021
PRIMARY